During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Panitumumab combined with FOLFOX improves survival and reduces recurrence in RAS/BRAF wild-type locally advanced colon cancer ...

Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...

During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in ...